Barbara W. Unger
President, Unger Consulting
Areas examined in this report:
- Why three manufacturing sites for COVID-19 vaccines and drugs received 483 observations
- An in-depth analysis of these observations based on the author’s expertise
- Learn how these observations stack up with observations at non-COVID products